Antag Therapeutics ApS

CVR 38402056 · Private limited company (ApS) · Active · Medium risk

Antag Therapeutics ApS is a Private limited company (ApS), founded on , based in København N. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 1.6% over the next 12 months, which is 1.1 times the average for Danish companies. 9 annual reports have been published, of which 2 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK 235k and a net result of DKK -201.0m.

Bankruptcy risk for Antag Therapeutics ApS

1.6%
probability of bankruptcy within 12 months
Medium risk

1.1 × the average (1.41%) · higher risk than 79% of active Danish companies

Lowest riskHighest risk

Increases the risk

Return on assets< -20% · bankruptcy rate 16.7%1.9×
Number of CEOs0 · bankruptcy rate 12.7%1.4×
CEOs in total (historical)0 · bankruptcy rate 12.4%1.4×
Website registeredYes · bankruptcy rate 12.0%1.4×
RegionHovedstaden · bankruptcy rate 11.6%1.3×
Other companies at the same address100+ · bankruptcy rate 11.5%1.3×
CEO's other companies0 · bankruptcy rate 10.9%1.2×
Share of late annual reports25%–50% · bankruptcy rate 10.6%1.2×

Reduces the risk

Time at current address5+ yrs · bankruptcy rate 3.1%0.35×
Number of auditors (historical)2 · bankruptcy rate 4.6%0.52×
Auditor registered in CVRYes · bankruptcy rate 4.8%0.55×
Audit opted outNo · bankruptcy rate 4.8%0.55×
Negative equityNo · bankruptcy rate 5.1%0.58×
Registered owners4+ · bankruptcy rate 5.7%0.65×
Reporting classReporting class B · bankruptcy rate 5.7%0.65×
Auditor's statementAudit · bankruptcy rate 5.8%0.66×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
38402056
Status
Active
Company type
Private limited company (ApS)
Founded
(9 years)
Address
Ole Maaløes Vej 3
2200 København N
Municipality
København
Industry
Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater
Share capital
DKK 488k
Employees
6 (2018)
Auditor
EY Godkendt Revisionspartnerselskab
Audit opted out
No

Warning signs

Annual reports filed late3 of 9
Missing annual reportNo
Negative equityNo
Equity ratio0.8%
Current ratio107%
Moves (last 2 years)0
CEO changes in total0
CEO's previous bankruptcies0
Other companies at the address167
Going-concern uncertaintyNo

Financials and key figures

Financial year20252024
Gross profitDKK -191.6mDKK -30.6m
Net profitDKK -201.0mDKK -32.3m
EquityDKK 235kDKK 201.2m
Total assetsDKK 28.0mDKK 225.4m
CashDKK 20.6m–
Short-term debtDKK 26.0m–
Avg. employees10–

Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · (venstre underskriver).

Filed annual reports

Reporting periodPublishedDays after period end
1 Jan 2025 – 31 Dec 2025163
1 Jan 2024 – 31 Dec 2024183
1 Jan 2023 – 31 Dec 2023183
1 Jan 2022 – 31 Dec 2022170
1 Jan 2021 – 31 Dec 2021186 Late
1 Jan 2020 – 31 Dec 2020197 Late
1 Jan 2019 – 31 Dec 2019175
1 Jan 2018 – 31 Dec 2018155
8 Feb 2017 – 31 Dec 2017159

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
BoardPhilip Just LarsenCurrent
BoardMark CurrieCurrent
BoardAmit Kantilal ShahCurrent
BoardAlexander Volker Wilhelm MaywegCurrent
BoardJørgen Søberg PetersenCurrent
BoardKeith Richard Leonard JrCurrent
BoardKirsten Aarup Drejer
BoardAnker Gunvald Lundemose
BoardEmmanuelle Coutanceau
BoardJens Juul Holst
BoardPieter Jeroen Bakker
BoardThomas Edward Needham Jr.
BoardChristine Theresa Fischette
BoardJayson Dallas
BoardJørgen Søberg Petersen
BoardAlexander Hovard Sparre-Ulrich
BoardJörg Möller
BoardJørgen Søberg Petersen
Owner (20%)Novo Holdings A/SCurrent
Owner (10%)Dawn Holdco SCSpCurrent
Owner (25%)Versant Venture Capital VII, L.P.Current
Owner (5%)SR One Capital Fund II Aggregator, LPCurrent
Owner (15%)Mette Marie Rosenkilde
Owner (15%)Jens Juul Holst
Owner (15%)Lark Holding ApS
Owner (33%)Sparre-Ulrich Holding ApS
Owner (5%)Mette Marie Rosenkilde
Owner (5%)Jens Juul Holst
Owner (33%)Novo Holdings A/S
Owner (5%)Lark Holding ApS
Owner (10%)Sparre-Ulrich Holding ApS
Owner (25%)Novo Holdings A/S
Owner (10%)Broadview Ventures I LLC
Owner (5%)VÆKSTFONDEN
Owner (5%)Broadview Ventures I LLC
Owner (5%)Danmarks Eksport- og Investeringsfond
Owner (5%)Dawn Holdco SCSp
Owner (20%)Versant Venture Capital VII, L.P.
Owner (5%)SR One Capital Fund II Aggregator, LP
Owner (10%)Dawn Holdco SCSp
Owner (15%)Versant Venture Capital VII, L.P.
Owner (10%)SR One Capital Fund II Aggregator, LP
AuditorEY Godkendt RevisionspartnerselskabCurrent
AuditorKPMG P/S
FounderMette Marie RosenkildeCurrent
FounderMaria Buur Nordskov GabeCurrent
FounderJens Juul HolstCurrent
FounderLAUSTSEN VENTURES ApSCurrent
FounderHealthcare Ventures ApSCurrent
FounderLark Holding ApSCurrent
FounderSparre-Ulrich Holding ApSCurrent

Address history (1 moves)

Ole Maaløes Vej 3, 2200 København N
Fælledvejens Passage 4, 4. th, 2200 København N

Former names

Antag Therapeutics ApS – now
Antag Therapeutics IVS –

Employees per year

Number of employees at Antag Therapeutics ApS per year362017: 420172018: 62018

Other companies at the same address

Similar companies in København

Questions and answers about Antag Therapeutics ApS

Has Antag Therapeutics ApS gone bankrupt?

No, Antag Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of Antag Therapeutics ApS?

Our model estimates a bankruptcy risk of 1.6% over the next 12 months (medium risk), which is 1.1 times the average for Danish companies.

Who is the auditor of Antag Therapeutics ApS?

Antag Therapeutics ApS most recently used EY Godkendt Revisionspartnerselskab.

When was Antag Therapeutics ApS founded?

Antag Therapeutics ApS was founded on 8 February 2017.

What is the equity of Antag Therapeutics ApS?

Equity was DKK 235k according to the annual report for the period ending 31 December 2025.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.